Current Trends in Cancer Therapy

Therapeutic agents in cancer are numerous and unique to different subtypes of malignancies. Given the different mechanisms of tumorigenesis including deleterious mutations, loss of important regulatory checkpoints, and proteins leading to uncontrolled cellular proliferation several means of targeted therapy exist. New agents in oncology including immune therapy, antiangiogenic drugs, targeted therapies, such as cyclin dependent kinase inhibitors help to target specific areas of the immune system and proliferation pathways to decrease tumor proliferation, growth, survival, and metastasis. This chapter serves to focus on the mechanisms of the new medications in cancer therapy that have changed the way we treat cancer.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/B978-0-12-803547-4.00001-X
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Nuclear PI3K signaling in cell growth and tumorigenesis

  2015cited by this paper
• Toxicities of Immunotherapy for the Practitioner.

  2015cited by this paper
• Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status

  2015cited by this paper
• Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Update on metastatic gastric and esophageal cancers.

  2015cited by this paper
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

  2015cited by this paper
• Immune Checkpoint Blockade in Cancer Therapy.

  2015cited by this paper
• Broad targeting of angiogenesis for cancer prevention and therapy

  2015cited by this paper
• Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

  2015cited by this paper
• Current status of the development of Ras inhibitors.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

  2015cited by this paper
• PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.

  2015cited by this paper
• Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer

  2015cited by this paper
• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

  2015cited by this paper
• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

  2015cited by this paper
• Rociletinib in EGFR-mutated non-small-cell lung cancer.

  2015cited by this paper
• Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

  2015cited by this paper
• Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award.

  2015cited by this paper
• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

  2014cited by this paper
• Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials

  2014cited by this paper
• Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

  2014cited by this paper
• Current perspectives on immunotherapy.

  2014cited by this paper
• Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

  2014cited by this paper
• Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

  2014cited by this paper
• Bevacizumab: A Review of Its Use in Advanced Cancer

  2014cited by this paper
• Cancer immunotherapy in clinical practice—the past, present, and future

  2014cited by this paper
• Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

  2014cited by this paper
• Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

  2014cited by this paper
• Mechanism of action of immunotherapy.

  2014cited by this paper
• Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

  2014cited by this paper
• Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

  2014cited by this paper
• Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

  2014cited by this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cited by this paper
• Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies

  2014cited by this paper
• Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

  2014cited by this paper
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

  2013cited by this paper
• Cabozantinib in progressive medullary thyroid cancer.

  2013cited by this paper
• Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

  2013cited by this paper
• ALK in lung cancer: past, present, and future.

  2013cited by this paper
• ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC

  2013cited by this paper
• 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

  2013cited by this paper
• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

  2013cited by this paper
• Therapeutic cancer vaccines: past, present, and future.

  2013cited by this paper
• Managing treatment-related adverse events associated with Alk inhibitors.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Cutaneous toxicities of RAF inhibitors.

  2013cited by this paper
• Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

  2013cited by this paper
• Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

  2013cited by this paper
• Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

  2013cited by this paper
• First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non‐interventional study

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• The mTOR Signalling Pathway in Human Cancer

  2012cited by this paper
• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

  2012cited by this paper
• Dabrafenib and its potential for the treatment of metastatic melanoma

  2012cited by this paper
• The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Immunotherapy of cancer in 2012

  2012cited by this paper
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

  2012cited by this paper
• Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

  2011cited by this paper
• Therapeutic strategies for targeting ras proteins.

  2011cited by this paper
• Inhibition of Ras for cancer treatment: the search continues.

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• Cancer immunotherapy comes of age.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• Molecular mechanisms and clinical applications of angiogenesis

  2011cited by this paper
• Recent Advances in Anti-Angiogenic Therapy of Cancer

  2011cited by this paper

• Therapeutic potential of TRPM8 channels in cancer treatment

  2023cites this paper
• Diagnosis of Colorectal Cancer Using Molecular Techniques

  2021cites this paper
• Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their γ-cyclodextrin solubilization

  2020cites this paper
• A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance

  2020cites this paper
• Internalized Functional DNA Aptamers as Alternative Cancer Therapies

  2020cites this paper